Idiopathic Parkinson Disease

Neurology
1
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

UP
UCB PharmaBelgium - Brussels
2 programs
1
LevetiracetamPhase 21 trial
Transdermal Rotigotine User Surveillance StudyN/A1 trial
Active Trials
NCT00599339Completed2,195Est. Apr 2014
NCT00160576Completed30Est. Nov 2004

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
UCB PharmaLevetiracetam
UCB PharmaTransdermal Rotigotine User Surveillance Study

Clinical Trials (2)

Total enrollment: 2,225 patients across 2 trials

Levetiracetam Treatment in Adult Subjects With Parkinson's Disease Experiencing Troublesome Dyskinesias

Start: Jul 2003Est. completion: Nov 200430 patients
Phase 2Completed
NCT00599339UCB PharmaTransdermal Rotigotine User Surveillance Study

Transdermal Rotigotine User Surveillance Study

Start: Jun 2006Est. completion: Apr 20142,195 patients
N/ACompleted

Related Jobs in Neurology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space